Table 2.
Concomitant antihypertensive medicationsa
| Placebo n = 27 | Losartan n = 26 | Spironolactone n = 27 | |
|---|---|---|---|
| At randomization (week 0) | |||
| Diuretic | 23 (85.2) | 23 (88.5) | 27 (96.3) |
| β-Blocker | 19 (70.4) | 17 (63.4) | 21 (77.8) |
| α-Blocker | 8 (29.6) | 8 (30.8) | 7 (25.9) |
| Central adrenergic agonist | 2 (7.4) | 3 (11.5) | 3 (11.1) |
| Vasodilator | 1 (3.7) | 0 (0) | 0 (0) |
| During active treatment (weeks 1 to 48) | |||
| Diuretic | 25 (92.6) | 24 (92.3) | 25 (92.6) |
| β-Blocker | 21 (77.8) | 22 (84.6) | 22 (81.5) |
| α-Blocker | 15 (55.6) | 16 (61.5) | 13 (48.2) |
| Central adrenergic agonist | 9 (33.3) | 11 (42.3) | 5 (18.5) |
| Vasodilator | 2 (7.4) | 2 (7.7) | 0 (0) |
| No. of concomitant antihypertensive medications during active treatment (weeks 1 to 48) | |||
| 0 | 2 (7.4) | 1 (3.9) | 2 (7.4) |
| 1 | 4 (14.8) | 4 (15.4) | 3 (11.1) |
| 2 | 5 (18.5) | 4 (15.4) | 9 (33.3) |
| 3 | 7 (25.9) | 7 (26.9) | 8 (29.6) |
| ≥4 | 9 (33.3) | 10 (38.5) | 5 (18.5) |
aData are presented as n (%). Treatment group differences are nonsignificant.